BioCryst Pharmaceuticals, Inc. Share Price
Stocks
BCRX
US09058V1035
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
01:29:56 27/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 9.830 USD | 0.00% |
|
-2.53% | +25.83% |
| 25/08 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
| 25/08 | BioCryst Pharmaceuticals Gets Japan Approval for Orladeyo in Young Children | MT |
| Market Cap | 251.19Cr 215.6Cr 202.36Cr 184.82Cr 348.8Cr 24TCr 350.49Cr 2.39TCr 928.08Cr 12TCr 943.15Cr 922.67Cr 40TCr | P/E 2026 * |
-4.28x | P/E 2027 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise Value | 251.19Cr 215.6Cr 202.36Cr 184.82Cr 348.8Cr 24TCr 350.49Cr 2.39TCr 928.08Cr 12TCr 943.15Cr 922.67Cr 40TCr | EV / Sales 2026 * |
3.58x | EV / Sales 2027 * | 3.41x |
| Free-Float |
94.77% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | -0.15% | ||
| 1 week | -2.53% | ||
| Current month | +9.30% | ||
| 1 month | +2.45% | ||
| 3 months | +15.88% | ||
| 6 months | +24.24% | ||
| Current year | +25.83% |
| 1 week | 9.48 |  | 9.99 |
| 1 month | 8.76 | | 10.68 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 01/01/2026 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 07/07/2025 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 06/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 01/01/2007 |
Theresa Heggie
BRD | Director/Board Member | 64 | 03/12/2018 |
Charles Gayer
BRD | Director/Board Member | 55 | 01/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/02/26 | Free | Chairman | 848 | 0.0003% | ||
| 27/02/26 | Free | Director | 1,285 | 0.0005% | ||
| 27/02/26 | Free | Director | 528 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -2.53% | +14.39% | +35.01% | 251.19Cr | |
| +3.31% | -3.70% | +61.03% | +103.64% | 7.14TCr | |
| +2.09% | +3.17% | +52.14% | +91.30% | 6.42TCr | |
| -1.33% | -0.47% | +7.44% | -6.70% | 2.86TCr | |
| +0.48% | -4.97% | -6.06% | +474.31% | 2.71TCr | |
| -2.78% | +4.47% | +52.49% | +14.43% | 2.73TCr | |
| -1.68% | +0.33% | +36.86% | -17.91% | 2.05TCr | |
| +1.02% | +6.43% | +269.42% | +420.34% | 1.94TCr | |
| -0.57% | -4.06% | +10.79% | +515.61% | 1.6TCr | |
| -1.06% | +4.28% | +47.94% | +155.73% | 1.41TCr | |
| Average | +0.02% | +3.75% | +54.65% | +178.58% | 2.91TCr | |
| Weighted average by Cap. | +0.82% | +3.26% | +55.12% | +153.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 70Cr 60Cr 57Cr 52Cr 98Cr 6.7TCr 98Cr 669.49Cr 259.45Cr 3.38TCr 263.67Cr 257.94Cr 11TCr | 74Cr 63Cr 59Cr 54Cr 102.38Cr 7.03TCr 102.87Cr 702.91Cr 272.4Cr 3.55TCr 276.83Cr 270.82Cr 12TCr |
| Net income | -58Cr -50Cr -47Cr -43Cr -80Cr -5.52TCr -81Cr -551.77Cr -213.83Cr -2.78TCr -217.31Cr -212.59Cr -9.22TCr | 18Cr 16Cr 15Cr 14Cr 26Cr 1.76TCr 26Cr 175.84Cr 68Cr 887.49Cr 69Cr 68Cr 2.94TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/26/27 | $9.825 | -0.05% | 11,88,860 |
| 25/26/25 | $9.830 | +1.55% | 23,32,655 |
| 24/26/24 | $9.680 | +1.36% | 20,10,324 |
| 21/26/21 | $9.550 | -1.14% | 24,96,708 |
| 20/26/20 | $9.660 | -4.07% | 23,29,247 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
